Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO) therapies using Secarna’s ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Have you ever spent hours crafting a timeline chart, only to abandon it because it was too clunky, rigid, or just plain uninspiring? You’re not alone. Many tools promise sleek visuals but fall short ...

Shares of Protalix BioTherapeutics (PLX) dropped after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on a proposed less frequent dosing ...

Fabry disease is a rare genetic lysosomal storage disorder in which the body lacks sufficient amounts of an enzyme that breaks down fats. The companies requested to approve the dosing regimen of 2 ...

DEER PARK, N.Y.--(BUSINESS WIRE)--Luxium Solutions, LLC (“Luxium” or the “Company”), a worldwide technology leader and provider of high-performance crystals used in photonics and radiation detection ...

Plexium has raised $60.1 million, providing an infusion of cash for the recently slimmed-down protein degrader specialist three years on from its breakout year. The biotech put itself on the map in ...

Protalix BioTherapeutics uses a plant-cell approach with ProCellEx. This has given it two approved ERTs plus PRX-115 and PRX-119. Its main focus is on a growing rare-disease pipeline. The main value ...

Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Second Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I ...

Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...

NI, which provides hardware and software for embedded and test applications, recently held its annual NI Connect event in Fort Worth, TX. Attendees got to see the latest products and technology for ...

The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. Having put up funding to help bring the candidate to market, the government terminated the contract in a ...